CSI Paris Tine Proesmans explains how screening for AF can be done in the general population using a smartphone and shares results of the DIGITAL-AF II study.
CSI Paris Camilla Bang shares preliminary results of her study on applying high-sensitive troponin results measured 30 minutes after admission to rule in or rule out acute MI in individuals with chest pain.
CSI Paris Eline Groenland asks Dan Lane about his novel screening method using urine samples that can detect whether hypertensive patients take their drugs. This test may help to improve medical adherence.
CSI Paris Cilie van 't Klooster asks prof. Mach to summarize the most important changes in the 2019 ESC/EAS dyslipidemia guidelines.
CSI Paris Gianluigi Savarese tells about his study using data of the SwedeHF registry on the associations between use of betablockers and all-cause and CV mortality in HFrEF patients aged >80 years.
ESC 2019 Prof.Freek Verheugt discusses the results of ISAR-REACT 5 in the broader context of the search for the best treatment for patients with CV disease.
CSI Paris Sanne Peters and Tamar de Vries talk about differences in impact of CV risk factors in women and men, and they highlight the need for awareness of sex-related differences in treatment effects.
ESC 2019 Frank Gommans presents a study on the association between levels of corin and neprilysin, enzymes involved in the metabolism of natriuretic peptides, and clinical outcomes in HF patients.
CSI Paris Jan Westerink tells about an exploratory analysis of the Look AHEAD trial, using a new prediction model to assess heterogeneity of treatment effects of an intensive lifestyle intervention on occurence of CV events in T2DM.
CSI Paris Steven Hageman asks Cilie van 't Klooster about her study on the relationship between CRP levels and risk of incident cancer and recurrent CV events in subjects with stable CVD in the SMART-cohort.
CSI Paris Eline Groenland interviews Tamar de Vries on lifetime models that can be used to estimate individual benefit and bleeding risk with addition of low-dose rivaroxaban to aspirin therapy in subjects with stable CVD.
ESC 2019 Prof. Cecilia Linde emphasizes known aspects of CVD in women, talks about the role of gender of the physician in outcomes of female patients and about the need for research of CVD in women.